The Role Of TGF-beta Signaling In Suppression Of Stat3-mediated Tumorigenesis
Funder
National Health and Medical Research Council
Funding Amount
$667,000.00
Summary
Stomach cancer is the third most prevalent cancer in the Western World and result in the yearly death of several thousand people in Australia alone. We have discovered a specifice gene mutation of a receptor molecule called gp130 that results in the formation of stomach cancer in mice. We are now aiming to understand the exact molecular events by which this mutation results in the uncontrolled growth of stomach mining cells. Our proposal combines the expertise of the two investigators in signal ....Stomach cancer is the third most prevalent cancer in the Western World and result in the yearly death of several thousand people in Australia alone. We have discovered a specifice gene mutation of a receptor molecule called gp130 that results in the formation of stomach cancer in mice. We are now aiming to understand the exact molecular events by which this mutation results in the uncontrolled growth of stomach mining cells. Our proposal combines the expertise of the two investigators in signal transduction and the making of genetically modified mouse models. These strategies will be employed to specifically address in the laboratory mouse the function of two specififc signaling cascades, called Stat3 and TGF-beta. The identification of detailed description by which these molecules causally relate to cancer formation will provide clear and specific molecular targets for future therapies to treat various cancers, including those of the stomach.Read moreRead less
Gastrokine 2: A Novel Stomach-specific Tumour Suppressor Gene
Funder
National Health and Medical Research Council
Funding Amount
$342,735.00
Summary
We will evaluate how a natural protein called gastrokine 2 acts to prevent cancer from developing in the stomach. We will show how gastrokine 2 interacts with another stomach protein TFF1, to block the effects of the inflammatory and cancer causing bacterium Helicobacter pylori, and the way that this bacterium circumvents this by turning off the production of gastrokine 2. Finally a drug which inhibits stomach tumour growth by turning on gastrokine 2 will be tested.